PRDX1-IN-4 is a PRDX1 inhibitor with an IC50 of 122 nM against human targets, exhibiting high subtype selectivity. It covalently binds to PRDX1, promoting ROS accumulation. The compound inhibits NLRP3 inflammasome activation, blocks hepatic stellate cell activation, and reduces collagen deposition. Additionally, PRDX1-IN-4 induces apoptosis (apoptosis) in activated hepatic stellate cells. It demonstrates good safety, with no significant weight loss or hepatotoxicity observed in mice at a dose of 20 mg/kg. At 1 mg/kg, PRDX1-IN-4 improves CCl4-induced liver injury and fibrosis in mice and is suitable for hepatic fibrosis research.